Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation

J Allergy Clin Immunol. 2019 Feb;143(2):794-797.e10. doi: 10.1016/j.jaci.2018.09.030. Epub 2018 Oct 16.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abelson murine leukemia virus / physiology*
  • Cytokines / metabolism
  • Dinoprostone / metabolism*
  • Humans
  • Imatinib Mesylate / pharmacology*
  • Inflammation
  • Leukemia / drug therapy*
  • Leukemia / genetics
  • Leukemia / immunology
  • Lipopolysaccharides / immunology
  • Monocytes / drug effects
  • Monocytes / physiology*
  • NF-kappa B / metabolism
  • Philadelphia Chromosome
  • Platelet Activation
  • Proto-Oncogene Proteins c-bcr / genetics*
  • Receptors, Prostaglandin E, EP4 Subtype / metabolism*
  • Signal Transduction
  • Th1-Th2 Balance
  • Thromboxane A2 / metabolism
  • U937 Cells

Substances

  • Cytokines
  • Lipopolysaccharides
  • NF-kappa B
  • Receptors, Prostaglandin E, EP4 Subtype
  • Thromboxane A2
  • Imatinib Mesylate
  • BCR protein, human
  • Proto-Oncogene Proteins c-bcr
  • Dinoprostone